Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Arch Therapeutics, Inc. (ARTH)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0460-0.0067 (-12.71%)
At close: 03:06PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0527
Open0.0476
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0423 - 0.0476
52 Week Range0.0400 - 0.1400
Volume78,283
Avg. Volume234,806
Market Cap10.905M
Beta (5Y Monthly)-0.46
PE Ratio (TTM)N/A
EPS (TTM)-0.0240
Earnings DateDec 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ARTH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ARCH THERAPEUTICS INC
    Analyst Report: Becton, Dickinson And Co.Headquartered in Franklin Lakes, New Jersey, BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, industry, and the general public. Its operations consist of three worldwide business segments: BD Medical, BD Life Sciences, and BD Interventional.
    Rating
    Fair Value
    Economic Moat
    7 days agoArgus Research
View more
  • GlobeNewswire

    Arch Therapeutics Provides Update on Reimbursement Strategy in Additional Selling Channel

    Initial A4100 code being deployed and application for specific HCPCS product code to be submitted in the second calendar quarterFRAMINGHAM, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided an update regarding its reimbursement strategy for the use of AC5® Advanced Wound System (“AC5”), specifically regarding its use in doctor’s offices and

  • GlobeNewswire

    Arch Therapeutics’ Experts in Wound Care Interview Showcases AC5 Self-Assembling Peptide Technology During Live Session at SAWC Spring

    World-renowned Wound Care Leaders, Terry Treadwell, MD, FACS and Brock Liden, DPM, Shared Insights on Success with AC5® Advanced Wound SystemFRAMINGHAM, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, announced today that the third interview in the Experts in Wound Care Program, a series of interviews with key opinion leaders dedicated to advancing wound

  • GlobeNewswire

    Renowned Wound Care Key Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Spring

    Additional data covered a variety of specialties, including vascular surgery, plastic surgery, general surgery, and podiatry, to further support clinical efficacy of AC5® Advanced Wound System in acute, chronic, and challenging wounds.FRAMINGHAM, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced that two clinical case reports on the use of

Advertisement
Advertisement